Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Down 80.9% in March

Virax Biolabs Group Limited (NASDAQ:VRAX) was the target of a large drop in short interest in the month of March. As of March 31st, there was short interest totalling 3,000 shares, a drop of 80.9% from the March 15th total of 15,700 shares. Currently, 0.2% of the company’s shares are short sold. Based on an average daily trading volume, of 84,800 shares, the days-to-cover ratio is currently 0.0 days.

Institutional Investors Weigh In On Virax Biolabs Group

Several institutional investors and hedge funds have recently bought and sold shares of the business. Armistice Capital LLC purchased a new stake in Virax Biolabs Group in the 4th quarter worth approximately $178,000. Virtu Financial LLC purchased a new stake in Virax Biolabs Group in the 4th quarter worth approximately $35,000. Legal & General Group Plc purchased a new stake in Virax Biolabs Group in the 4th quarter worth approximately $73,000. Finally, UBS Group AG purchased a new position in shares of Virax Biolabs Group in the 3rd quarter valued at approximately $38,000. Hedge funds and other institutional investors own 8.61% of the company’s stock.

Virax Biolabs Group Trading Up 1.2 %

NASDAQ VRAX opened at $0.78 on Thursday. Virax Biolabs Group has a fifty-two week low of $0.70 and a fifty-two week high of $8.54. The stock has a 50 day simple moving average of $0.84 and a two-hundred day simple moving average of $1.63.

Virax Biolabs Group Company Profile

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.